Attovia Therapeutics (NASDAQ:ATTO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Attovia Therapeutics (NASDAQ:ATTO) to a sell rating in a research note published on Saturday,Wall Street Zen reports.

Other equities research analysts have also issued research reports about the stock. Zacks Research upgraded shares of Attovia Therapeutics to a “hold” rating in a research note on Friday, September 4th. Royal Bank Of Canada initiated coverage on Attovia Therapeutics in a report on Monday, August 31st. They issued an “outperform” rating and a $45.00 price objective for the company. Morgan Stanley initiated coverage on Attovia Therapeutics in a research note on Monday, August 31st. They set an “overweight” rating and a $39.00 price objective on the stock. Citigroup initiated coverage on Attovia Therapeutics in a report on Monday, August 31st. They set a “buy” rating and a $30.00 target price on the stock. Finally, Leerink Partners assumed coverage on Attovia Therapeutics in a research report on Monday, August 31st. They issued an “outperform” rating and a $52.00 target price for the company. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, Attovia Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.20.

Attovia Therapeutics Trading Down 3.8%

Attovia Therapeutics stock opened at $21.30 on Friday. Attovia Therapeutics has a 52 week low of $16.15 and a 52 week high of $28.00.

Attovia Therapeutics (NASDAQ:ATTO) last posted its quarterly earnings results on Wednesday, September 2nd. The company reported ($4.88) earnings per share (EPS) for the quarter. The company had revenue of $0.45 million for the quarter. As a group, equities research analysts forecast that Attovia Therapeutics will post -4.06 EPS for the current year.

Insiders Place Their Bets

In other Attovia Therapeutics news, major shareholder Life Sciences Xi L.P. Frazier acquired 588,235 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was acquired at an average price of $17.00 per share, with a total value of $9,999,995.00. Following the transaction, the insider directly owned 6,154,213 shares in the company, valued at approximately $104,621,621. This represents a 10.57% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Colin Walsh acquired 500,000 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The shares were acquired at an average price of $17.00 per share, for a total transaction of $8,500,000.00. Following the purchase, the director owned 3,020,632 shares of the company’s stock, valued at $51,350,744. This trade represents a 19.84% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders acquired 2,740,587 shares of company stock worth $47,269,979.

About Attovia Therapeutics

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biotechnology company focused on developing antibody-based medicines for immune-mediated and inflammatory diseases. Its research programs are designed to address conditions in which dysregulated immune signaling contributes to disease.

The company’s activities include discovering, developing and advancing biologic drug candidates through preclinical and clinical testing. Attovia’s pipeline is centered on targeted therapies intended to modulate key pathways involved in inflammation and immune responses, with the goal of treating patients with significant unmet medical needs.

Attovia Therapeutics is headquartered in the United States and operates as a development-stage biopharmaceutical company.